ArticleEuropean radiology experimental2022
Radiologic-pathologic correlation in breast cancer: do MRI biomarkers correlate with pathologic features and molecular subtypes?
Article in European radiology experimental, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Association of peritumoral region features assessed on breast MRI and prognosis of breast cancer: a systematic review and meta-analysis.European radiology · 2024Pooled it
- A deep learning system for non-invasive breast cancer diagnosis with multimodal data.Nature biomedical engineering · 2026Article
- MRI-based habitat and peritumoral radiomics for predicting HER2 status in breast cancer: a multicenter study.Scientific reports · 2026Article
- Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy.European radiology · 2026Article
- Case report of invasive ductal carcinoma of the breast in a Pakistani male aged 55.Discover oncology · 2026Article
- A pilot study of multimodal MRI for the preoperative assessment of triple-negative breast cancer.Frontiers in oncology · 2026Article
- Review
- Prediction of neoadjuvant chemotherapy efficacy in breast cancer: integrating multimodal imaging and clinical features.BMC medical imaging · 2025Article
- Critical dialogue: recent advancements toward omission of axillary lymph node dissection in clinically node positive breast cancer patients treated with neoadjuvant chemo-immuno therapy: impact on radiology practice.Insights into imaging · 2025Article
- Correlations of Imaging and Therapy in Breast Cancer Based on Molecular Patterns: An Important Issue in the Diagnosis of Breast Cancer.International journal of molecular sciences · 2024Review
- Article
- Digital Mammography (DM) vs. Dynamic Contrast Enhancement-Magnetic Resonance Imaging (DCE-MRI) in Microcalcifications Assessment: A Radiological-Pathological Comparison.Diagnostics (Basel, Switzerland) · 2024Article
- Characterization and antitumor effect of doxorubicin-loaded FeRSC advances · 2024Article
- Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know.Radiology. Imaging cancer · 2023Review
- Classifying Breast Cancer Metastasis Based on Imaging of Tumor Primary and Tumor Biology.Diagnostics (Basel, Switzerland) · 2023Review
- Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence ScoreDiagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) includes different pathological and molecular subtypes. This study aimed to investigate whether multiparametric magnetic resonance imaging (mpMRI) could reliably predict the molecular status of BC, comparing mpMRI features with pathological and immunohistochemical results.
methodsThis retrospective study included 156 patients with an ultrasound-guided biopsy-proven BC, who underwent breast mpMRI (including diffusion-weighted imaging) on a 3-T scanner from 2017 to 2020. Histopathological analyses were performed on the surgical specimens. Kolmogorov-Smirnov Z, χ
resultsFifteen patients were affected with ductal carcinoma in situ, 122 by invasive carcinoma of no special type, and 19 with invasive lobular carcinoma. Out of a total of 141 invasive cancers, 45 were luminal A-like, 54 luminal B-like, 5 human epidermal growth factor receptor 2 (HER2) positive, and 37 triple negative. The regression analyses showed that size < 2 cm predicted luminal A-like status (p = 0.025), while rim enhancement (p < 0.001), intralesional necrosis (p = 0.001), peritumoural oedema (p < 0.001), and axillary adenopathies (p = 0.012) were negative predictors. Oppositely, round shape (p = 0.001), rim enhancement (p < 0.001), intralesional necrosis (p < 0.001), and peritumoural oedema (p < 0.001) predicted triple-negative status.
conclusionsmpMRI has been confirmed to be a valid noninvasive predictor of BC subtypes, especially luminal A and triple negative. Considering the central role of pathology in BC diagnosis and immunohistochemical profiling in the current precision medicine era, a detailed radiologic-pathologic correlation seems vital to properly evaluate BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.